Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
Among patients with T2DM, GLP-1 RA users demonstrated a significantly lower risk of developing IBD than basal insulin and DPP-4i users. GLP-1 RA users also showed a lower risk of hospitalisation. GLP-1 RAs may contribute to lowering the risk of IBD in individuals with T2DM.
Authors
- Chih‐Cheng Hsu (ORCID: https://orcid.org/0000-0003-4563-4341)
- Fu‐Shun Yen (ORCID: https://orcid.org/0000-0002-4677-2415)
- Chii‐Min Hwu (ORCID: https://orcid.org/0000-0002-8209-9627)
- Shiow‐Ing Wang (ORCID: https://orcid.org/0000-0003-3407-9020)
- Yao‐Min Hung (ORCID: https://orcid.org/0000-0001-6920-8799)
Institutions
- Ministry of Health and Welfare (KR)
- National Yang Ming Chiao Tung University (TW)
- National Health Research Institutes (TW)
- National Taitung University (TW)
- China Medical University (TW)
- Min Sheng General Hospital (TW)
- Taipei Veterans General Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Ministry of Health and Welfare (TW)
- Taichung Hospital (TW)
- Meiho University (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1111/dom.70034
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chung Shan Medical University Hospital